Stock detail

Alumis (ALMS) stock price, chart, and key data

View Alumis stock price, chart movement, and headline metrics on Woodstock's stock detail page.

ALMS

Stock detail

Alumis

ALMS · XNAS

-$4.19 (-14.55%) past day

$24.61

Overnight $24.63 (+0.08%)

XNAS24/5 tradingLast updated: Jul 25, 01:01 PM

Key metrics

Earnings

Quarterly results and the next expected release

0.770.21-0.35-0.91-1.47
FY2025 Q2Reported EPS: 0.77Expected EPS: -1.47
FY2025 Q3Expected EPS: -1.06
FY2025 Q4Reported EPS: -0.89Expected EPS: -0.25
FY2026 Q1Expected EPS: -0.74
FY2026 Q2
FY2026 Q3

FY25 Q2

Q3

Q4

FY26 Q1

Q2

Q3

Reported EPSExpected EPS

Day range

$26.99 - $29.02

Close price

$28.30

Market cap

$3.6B

P/E ratio

-33.26

About the company

Alumis Inc

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Ticker holders

Review politician disclosures and insider transactions in tabs.

No holder data is available for this category yet.

Market action

A concise summary of the latest filing, transaction, or market-moving item.

Alumis Inc. (ALMS) reported an insider ownership change by Sanam Pangali in a Form 4 filed July 8, 2026, covering a transaction dated July 6, 2026. The filing reports a transaction involving Alumis common stock tied to 5,000 shares at $5.06 per share. The explanatory note indicates the securities are associated with an option award: 25% of the shares underlying the option vested on February 18, 2026, with the remaining shares scheduled to vest in equal monthly installments over the following 36 months. Continued vesting is subject to Pangali’s “Continuous Service” to Alumis, as defined under the company’s 2024 Equity Incentive Plan, and the award is also subject to possible acceleration. The filing text does not show a transaction code in the provided extract, nor does it provide a complete post-transaction beneficial ownership total for Pangali. Based on the vesting footnote, the reported action appears to involve an equity incentive option covering 5,000 shares of Alumis common stock with a $5.06 per-share price, rather than an open-market stock trade. Pangali signed the filing on July 8, 2026. The disclosure matters because it records insider equity compensation activity and provides investors with details about the timing, size, price, and vesting conditions of the insider’s Alumis-linked securities.

24/5 Trading

Act on the stock when the timing works for you.

With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.

*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.

Download the app
24/5 trading chart preview

Sign Up

Scan the QR code to get started

Contact via LINE

Scan the QR code to get started

LINE QR Code